Investor Relations

Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer. Merrimack applies its systems biology-based approach to biomedical research, throughout the research and development process. Merrimack currently has six targeted therapeutic oncology candidates in clinical development.

View all »   RSSRecent Releases

Feb 26, 2015
Merrimack Pharmaceuticals Reports Fourth Quarter 2014 Financial Results

Feb 19, 2015
Merrimack Pharmaceuticals Announces Initiation of a Phase 2 Biomarker-Selected Clinical Trial of MM-121 in Patients with Heregulin Positive Non-Small Cell Lung Cancer

Feb 12, 2015
Merrimack Pharmaceuticals Announces Timing of Fourth Quarter 2014 Investor Conference Call

Jan 22, 2015
Merrimack Pharmaceuticals Names Birgit M. Schoeberl, Ph.D. as Head of Discovery Division and Announces the Addition of Ulrik B. Nielsen, Ph.D. to Its Board of Directors

View all »Events & Presentations

Mar 2, 2015 at 3:30 PM ET
Cowen and Company 35th Annual Health Care Conference

Mar 10, 2015 at 3:20 PM ET
Barclays Global Healthcare Conference

Stock Quote (NASDAQ: MACK)

Price:
11.11

Change:
+ 0.39

Day High:
11.11

Day Low:
10.70

Volume:
623,400

1:42 PM ET on Mar 2, 2015
Delayed ~20 min. By eSignal.

Shareholder Tools